| Emerging drugs for perennial allergic rhinitis. | |
| | |
MedLine Citation:
|
PMID: 23186314 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Introduction: Allergic rhinitis (AR) is a high-prevalence disease, sustained by an IgE-triggered reaction with histamine release, followed by an inflammatory response which involves cells, mediators, cytokines and adhesion molecules. According to its duration, AR can be either intermittent or persistent. In the persistent form, the inflammatory component usually predominates. Areas covered: The current therapeutic strategy is based on antihistamines, antileukotrienes and on corticosteroids (which broadly act on inflammation). Allergen-specific immunotherapy is a biological response modifier that affects the immune response to allergens in a broad sense. The available pharmacotherapy is overall effective in controlling symptoms and inflammation, but safety concerns may be present (especially for prolonged treatments), and a proportion of patients remain uncontrolled. The available therapeutic innovations, as derived from the most recent literature are reviewed herein. Expert opinion: In the last years there have been very few innovative approaches to optimize the management of AR. These include new histamine receptor antagonists, combination therapy and strategies to selectively block relevant signaling pathways of the allergic reaction. Some more promising advances have been shown for allergen immunotherapy, where a number of new strategies are currently under development. |
| | |
Authors:
|
Giovanni Passalacqua; Giorgio Ciprandi |
Related Documents
:
|
12761894 - Nitric oxide synthase i mediates osteoclast activity in vitro and in vivo. 14769514 - Role for osteoprotegerin in rheumatoid inflammation. 19049324 - Osteocyte apoptosis controls activation of intracortical resorption in response to bone... 9823004 - Active role of chondrocyte apoptosis in endochondral ossification. 21572994 - Antigen-independent ifn-γ production by human naïve cd4 t cells activated by il-12 pl... 19201824 - Involvement of tlr2 in innate response to bacillus anthracis infection. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on emerging drugs Volume: 17 ISSN: 1744-7623 ISO Abbreviation: Expert Opin Emerg Drugs Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-11-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101135662 Medline TA: Expert Opin Emerg Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 543-53 Citation Subset: IM |
Affiliation:
|
Allergy & Respiratory Diseases, IRCCS S. Martino-IST-University of Genoa , Padiglione Maragliano, L.go R. Benzi 10, 16132 Genoa , Italy + 39 10 3538908 ; + 39 10 3538904 ; passalacqua@unige.it. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preop...
Next Document: Emerging drugs for myelofibrosis.